Individual
DC projects
Research project
Prevent Progression of Myelofibrosis to Acute Myeloid Leukemia
Rationale and Objectives
This project aims to uncover the genetic and epigenetic drivers of Myelofibrosis (MF) progression to AML using advanced sequencing and CRISPR technologies, with the ultimate goal of developing targeted therapies to block disease progression.
The specific objectives are:
- Identifying MF clones predisposed to AML through novel single-cell sequencing technologies, including direct nuclear tagmentation and RNA sequencing (DNTR-seq), as well as single-cell ATAC-seq.
- Investigating epigenetic regulators facilitating disease progression using CRISPR/Cas9 knockout strategies in CALR-mutated MF patient-derived iPSCs, to reveal potential therapeutic targets.
- Developing targeted treatments in MF iPSC models by focusing on identified epigenetic regulators, with validation performed in a 3D bone marrow mimicking culture system.
Estimated gross salary
56,100€/year
This project may be adapted to the evolving needs of the host laboratory while remaining within hemato-oncology research. The DC will undertake one or more secondments with a total duration of at least three months and up to one year. These secondments may take place within or outside the DN, preferably in international and intersectoral settings.